These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
132 related articles for article (PubMed ID: 8242835)
1. In vitro tests to predict in vivo performance of liposomal dosage forms. Amselem S; Cohen R; Barenholz Y Chem Phys Lipids; 1993 Sep; 64(1-3):219-37. PubMed ID: 8242835 [TBL] [Abstract][Full Text] [Related]
2. Improved therapeutic responses in a xenograft model of human B lymphoma (Namalwa) for liposomal vincristine versus liposomal doxorubicin targeted via anti-CD19 IgG2a or Fab' fragments. Sapra P; Moase EH; Ma J; Allen TM Clin Cancer Res; 2004 Feb; 10(3):1100-11. PubMed ID: 14871990 [TBL] [Abstract][Full Text] [Related]
3. Influence of lipid composition on the antitumor activity exerted by doxorubicin-containing liposomes in a rat solid tumor model. Storm G; Roerdink FH; Steerenberg PA; de Jong WH; Crommelin DJ Cancer Res; 1987 Jul; 47(13):3366-72. PubMed ID: 3581073 [TBL] [Abstract][Full Text] [Related]
4. Drug release rate influences the pharmacokinetics, biodistribution, therapeutic activity, and toxicity of pegylated liposomal doxorubicin formulations in murine breast cancer. Charrois GJ; Allen TM Biochim Biophys Acta; 2004 May; 1663(1-2):167-77. PubMed ID: 15157619 [TBL] [Abstract][Full Text] [Related]
5. Kinetic analysis of tissue distribution of doxorubicin incorporated in liposomes in rats (II). Harashima H; Midori Y; Ohshima S; Yachi K; Kikuchi H; Kiwada H Biopharm Drug Dispos; 1993 Oct; 14(7):595-608. PubMed ID: 8251614 [TBL] [Abstract][Full Text] [Related]
6. Release of doxorubicin from peritoneal macrophages exposed in vivo to doxorubicin-containing liposomes. Storm G; Steerenberg PA; Emmen F; van Borssum Waalkes M; Crommelin DJ Biochim Biophys Acta; 1988 May; 965(2-3):136-45. PubMed ID: 3365449 [TBL] [Abstract][Full Text] [Related]
7. Sonosensitive dioleoylphosphatidylethanolamine-containing liposomes with prolonged blood circulation time of doxorubicin. Evjen TJ; Hagtvet E; Nilssen EA; Brandl M; Fossheim SL Eur J Pharm Sci; 2011 Jul; 43(4):318-24. PubMed ID: 21620968 [TBL] [Abstract][Full Text] [Related]
8. Albumin-conjugated PEG liposome enhances tumor distribution of liposomal doxorubicin in rats. Yokoe J; Sakuragi S; Yamamoto K; Teragaki T; Ogawara K; Higaki K; Katayama N; Kai T; Sato M; Kimura T Int J Pharm; 2008 Apr; 353(1-2):28-34. PubMed ID: 18082345 [TBL] [Abstract][Full Text] [Related]
9. In vitro and in vivo targeting of immunoliposomal doxorubicin to human B-cell lymphoma. Lopes de Menezes DE; Pilarski LM; Allen TM Cancer Res; 1998 Aug; 58(15):3320-30. PubMed ID: 9699662 [TBL] [Abstract][Full Text] [Related]
10. The influence of physical characteristics of liposomes containing doxorubicin on their pharmacological behavior. Goren D; Gabizon A; Barenholz Y Biochim Biophys Acta; 1990 Nov; 1029(2):285-94. PubMed ID: 2245212 [TBL] [Abstract][Full Text] [Related]
11. Comparative plasma and tissue distribution of Sun Pharma's generic doxorubicin HCl liposome injection versus Caelyx Burade V; Bhowmick S; Maiti K; Zalawadia R; Jain D; Rajamannar T Cancer Chemother Pharmacol; 2017 May; 79(5):899-913. PubMed ID: 28349166 [TBL] [Abstract][Full Text] [Related]
12. Pharmacokinetics and tissue distribution of doxorubicin encapsulated in stable liposomes with long circulation times. Gabizon A; Shiota R; Papahadjopoulos D J Natl Cancer Inst; 1989 Oct; 81(19):1484-8. PubMed ID: 2778836 [TBL] [Abstract][Full Text] [Related]
13. Investigation of factors affecting in vitro doxorubicin release from PEGylated liposomal doxorubicin for the development of in vitro release testing conditions. Shibata H; Izutsu K; Yomota C; Okuda H; Goda Y Drug Dev Ind Pharm; 2015; 41(8):1376-86. PubMed ID: 25170659 [TBL] [Abstract][Full Text] [Related]
14. In vivo evaluation of doxorubicin carried with long circulating and remote loading proliposome. Junping W; Maitani Y; Takayama K; Nagai T Int J Pharm; 2000 Aug; 203(1-2):61-9. PubMed ID: 10967428 [TBL] [Abstract][Full Text] [Related]
15. Effect of repetitive administration of Doxorubicin-containing liposomes on plasma pharmacokinetics and drug biodistribution in a rat brain tumor model. Arnold RD; Mager DE; Slack JE; Straubinger RM Clin Cancer Res; 2005 Dec; 11(24 Pt 1):8856-65. PubMed ID: 16361575 [TBL] [Abstract][Full Text] [Related]
16. Development of an in vitro drug release assay of PEGylated liposome using bovine serum albumin and high temperature. Hioki A; Wakasugi A; Kawano K; Hattori Y; Maitani Y Biol Pharm Bull; 2010; 33(9):1466-70. PubMed ID: 20823558 [TBL] [Abstract][Full Text] [Related]
17. Enhanced tumor targeting of doxorubicin by ganglioside GM1-bearing long-circulating liposomes. Unezaki S; Maruyama K; Ishida O; Takahashi N; Iwatsuru M J Drug Target; 1993; 1(4):287-92. PubMed ID: 8069570 [TBL] [Abstract][Full Text] [Related]
18. Effects of intraperitoneal administration of free and liposome-entrapped doxorubicin on rat peritoneal exudate cell populations. Storm G; Steerenberg PA; Van Borssum Waalkes M; Crommelin DJ J Drug Target; 1996; 4(4):255-64. PubMed ID: 9010815 [TBL] [Abstract][Full Text] [Related]
19. Targeted delivery and triggered release of liposomal doxorubicin enhances cytotoxicity against human B lymphoma cells. Ishida T; Kirchmeier MJ; Moase EH; Zalipsky S; Allen TM Biochim Biophys Acta; 2001 Dec; 1515(2):144-58. PubMed ID: 11718670 [TBL] [Abstract][Full Text] [Related]
20. Efficacy, biodistribution, and pharmacokinetics of CD22-targeted pegylated liposomal doxorubicin in a B-cell non-Hodgkin's lymphoma xenograft mouse model. Tuscano JM; Martin SM; Ma Y; Zamboni W; O'Donnell RT Clin Cancer Res; 2010 May; 16(10):2760-8. PubMed ID: 20460479 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]